




# The 22<sup>nd</sup> Korean Society of Hematology AML/MDS Working Party Symposium The 8<sup>th</sup> Japan-Korea Joint Symposium



**15<sup>th</sup> SEP (Sat), 2018**

Hall 337, Central Administration Building,  
Severance Hospital, Yonsei University, Seoul

09:20~09:40 Registration  
09:40~09:50 Opening Remark

## JOINT SESSION I: Current Treatment for MDS in Japan and Korea

Chaired by Itaru Matsumura (Kinki University), Je-Hwan Lee (University of Ulsan)

09:50~10:20	Long term use of hypomethylating agents for MDS	June-Won Cheong (Yonsei University)
10:20~10:50	JALSG AML/MDS/CMML clinical observational study - Preliminary report of the MDS part-	Kensuke Usuki (NTT Medical Center Tokyo)
10:50~11:20	Genetic mutations and decision-making of treatment options for MDS	Yoo-Jin Kim (The Catholic University of Korea)
11:20~11:50	Preliminary report of AZA trial for high risk MDS, MDS212 on behalf of JALSG	Yasushi Miyazaki (Nagasaki University)

## JOINT SESSION II: Study Proposals for Collaboration between JALSG & KSH AML/MDS WP

Chaired by Hitoshi Kiyoi (Nagoya University), Hee-Je Kim (The Catholic University of Korea)

11:50~12:05	<b>Study Proposal (I)</b> Prospective study of the induction Regimen for acute non-Promyelocytic Leukemia in Elderly; Hypomethylating agents for favorable risk (PURPLE-H)	Hawk Kim (Gachon University)
12:05~12:20	<b>Study Proposal (II)</b> Beyond hypomethylating agent (HMA) failure in AML patients	Silvia Park (The Catholic University of Korea)
12:20~12:35	<b>Study Proposal (III)</b> Comparative study on MDS between Korea and Japan	Yasushi Miyazaki (Nagasaki University)
12:35~13:30	Lunch	

## SESSION III: The Current Landscape of AML Approaches

Chaired by Hyeoung Joon Kim (Chonnam National University), Dong Soon Lee (Seoul National University)

13:30~13:55	Decision between epigenetic therapy and chemotherapy in patients with AML	Hyewon Lee (National Cancer Center)
13:55~14:20	Genomics of myeloid malignancies	Young-Uk Cho (University of Ulsan)
14:20~14:30	Coffee Break	

## SESSION IV: The Role of Targeted Therapy in the Management of Patients with AML

Chaired by Inho Kim (Seoul National University), Chul Won Jung (Sungkyunkwan University)

14:30~14:55	Target Therapy	Dong-Yeop Shin (Seoul National University)
14:55~15:20	CAR-T Therapy, Immune Checkpoint and Vaccine Approaches in AML	Jun Ho Jang (Sungkyunkwan University)
15:20~15:30	Grand Meeting	



The Korean Society of Hematology

